Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

349.00DKK
28 Mar 2017
Change (% chg)

kr.0.00 (+0.00%)
Prev Close
kr.349.00
Open
--
Day's High
--
Day's Low
--
Volume
559
Avg. Vol
197,454
52-wk High
kr.359.00
52-wk Low
kr.197.00

Select another date:

Wed, Mar 15 2017

BRIEF-Bavarian Nordic FY EBIT rises to DKK 33.0 million

* FY revenue 1.01 billion Danish crowns ($145 million) versus 1.02 billion crowns year ago

BRIEF-Bavarian Nordic: collaboration to evaluate CV301 and Tecentriq in bladder cancer

* Announces collaboration to evaluate CV301 and tecentriq in bladder cancer

BRIEF-Bavarian Nordic announces 6-mth follow-up data from phase 1 trial of MVA-BN RSV

* Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

BRIEF-Bavarian Nordic Q3 EBIT swings to profit of DKK 124.8 million

* Q3 revenue 452.3 million Danish crowns ($68.1 million) versus 79.1 million crowns year ago

BRIEF-Bavarian Nordic starts Phase 2 clinical trial of RSV vaccine

* Top-line results from study are anticipated around mid-2017

BRIEF-Bavarian Nordic starts Phase 2 combination trial of PROSTVAC and Ipilimumab

* Announces initiation of Phase 2 combination trial of PROSTVAC and Ipilimumab in patients with localized prostate cancer

Select another date:

More From Around the Web